[{"orgOrder":0,"company":"Grace","sponsor":"Acasti Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nimodipine","moa":"Voltage-gated L-type calcium channel subunit beta-4","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Grace","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Intravenous infusion","sponsorNew":"Grace \/ Acasti Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Grace \/ Acasti Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Grace

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Grace provides Acasti with a pipeline of rare and orphan disease programs. Grace's GTX-104 is a Novel aqueous nanoparticle formulation of water insoluble nimodipine, is believed to potentially improve the management of hypotension and vasospasm in SAH pa...

                          Brand Name : GTX-104

                          Molecule Type : Small molecule

                          Upfront Cash : $64.0 million

                          May 07, 2021

                          Lead Product(s) : Nimodipine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Acasti Pharma

                          Deal Size : $64.0 million

                          Deal Type : Acquisition

                          blank